Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15216691 | 0.76 | — | — | |
| SCHEMBL20099437 | 0.69 | TBXAS1 (0.32) | — | |
| SCHEMBL2697302 | 0.69 | CYP11B1 (0.50) | — | |
| SCHEMBL218490 | 0.67 | TP53 (0.31) | TP53 | |
| SCHEMBL19700911 | 0.66 | PI4KA (0.33) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22083730 | 0.66 | ALPL (0.38) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11238833 | 0.64 | ESR1 (0.31) | — | |
| SCHEMBL11238843 | 0.64 | ESR1 (0.31) | — | |
| SCHEMBL4019277 | 0.64 | TP53 (0.30) | TP53L3MBTL1 | |
| SCHEMBL15932248 | 0.64 | MEN1 (0.54) | TP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2021-03-25 | — | — | US | disclosed |
| US-9845295-B2 | Triphenylethylene compounds and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845295-B2 | Triphenylethylene compounds and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170144975-A1 | TRIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2017-05-25 | — | — | US | disclosed |
| US-20170144975-A1 | TRIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2017-05-25 | — | — | US | disclosed |
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150306086-A1 | MODULATING CERTAIN TYROSINE KINASES | TESARO, INC. | 2015-10-29 | — | — | US | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9090621-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-8957080-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8946241-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140336382-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140309223-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140303161-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2014-10-09 | — | — | US | disclosed |
| US-8759358-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2066659-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | PI4KA 28/4885PI4K2B 99/4885PI4K2A 168/4885 |
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | PI4KA 75/4885PI4K2B 68/4885PI4K2A 67/4885 |
| US-20150306086-A1 | MODULATING CERTAIN TYROSINE KINASES | ABL1, LCK, FLT3 | PI4KA 273/4885PI4K2B 328/4885PI4K2A 394/4885 |
| US-20170144975-A1 | TRIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CYP19A1, ESR1, ESRRA | PI4KA 942/4885PI4K2B 1508/4885PI4K2A 1319/4885 |
| US-20140303161-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | PI4KA 75/4885PI4K2B 68/4885PI4K2A 67/4885 |
| US-20140336382-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | PI4KA 75/4885PI4K2B 68/4885PI4K2A 67/4885 |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | PI4KA 28/4885PI4K2B 99/4885PI4K2A 168/4885 |
| US-20140309223-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | PI4KA 75/4885PI4K2B 68/4885PI4K2A 67/4885 |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | PI4KA 1447/4885PI4K2B 1715/4885PI4K2A 2318/4885 |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | PAFAH1B3, PAFAH1B2, PAF1 | PI4KA 992/4885PI4K2B 1403/4885PI4K2A 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.